Clinical trials: Rheumatoid Arthritis
Rheumatoid Arthritis
Rheumatoid Arthritis Patients on Adalimumab to Evaluate Its Effect on Synovitis Using Ultrasonography in an Egyptian Population
This Post-Marketing Observational Study (PMOS) was conducted to assess the effectiveness of adalimumab on reducing synovitis (inflammation of the synovial membrane, which lines movable synovial joints, such as shoulders, elbows…
- Trial name
- NCT01782469
- Volunteers
- 16 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
A Study to Evaluate Tocilizumab Treatment in a Real-Life Setting
This observational, multi-center study will evaluate the treatment regimen, treatment responses and safety of tocilizumab therapy in a routine clinical practice in participants with moderate to severe rheumatoid arthritis (RA).
- Trial name
- NCT01664104
- Testing
- Tocilizumab
- Where
- 24 sites in Italy
- Volunteers
- 151 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb
The purpose of this study is to determine whether the blood levels of Abatacept (BMS-188667) drug product manufactured at Lonza Biologics and the Devens, MA facility of Bristol-Myers Squibb are comparable in healthy subjects
- Trial name
- NCT01439204
- Testing
- Abatacept (BMS-188667)
- Where
- United States
- Volunteers
- 223 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Arthritis, Gout
Phone-Based Based Walk With Ease Program for Adults With Arthritis
The objective of this study is to examine the short-term (6-weeks and 6 months) and long-term (1 year) effects of a phone-based version of Walk With Ease intervention.
- Conditions
- Arthritis, Gout, Fibromyalgia, Rheumatoid Arthritis
- Trial name
- NCT05289544
- Testing
- Phone-Based Walk With Ease
- Where
- United States
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- University of South Carolina
Rheumatoid Arthritis
A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease
This is a multicenter, two-part, randomized, double-blind, placebo-kontrolled, 4-week study with repeated doses of AP1189. The study population will consist of newly diagnosed subjects with severe active Rheumatoid Arthritis…
- Trial name
- BEGIN (NCT04004429)
- Testing
- 50 mg AP1189, AP1189
- Where
- 2 sites in Denmark, Norway
- Volunteers
- 105 people
- Sponsor
- SynAct Pharma Aps
Rheumatoid Arthritis
A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis
This is a Phase III, open-label study of a total of approximately 560 subjects with active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs).
- Trial name
- SUNDIAL (NCT00443651)
- Testing
- Rituximab, Anti-inflammatory drugs
- Volunteers
- 578 people
- Sponsor
- Genentech, Inc.
Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome (ALPS)
Sirolimus for Autoimmune Disease of Blood Cells
Treatment for patients with autoimmune destruction of blood cells is poor. The part of the body that fights infections is called the immune system and white blood cells (WBCs) are part of the immune system.
- Conditions
- Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome (ALPS), Evans Syndrome, Idiopathic Thrombocytopenic Purpura
- Trial name
- NCT00392951
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital of Philadelphia
Rheumatoid Arthritis
Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients
This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory agent, will improve the clinical condition of patients with rheumatoid arthritis who still have active joint inflammation despite taking…
- Trial name
- NCT00556894
- Testing
- CF101
- Where
- 26 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 253 people
- Sponsor
- Can-Fite BioPharma
Systemic Juvenile Idiopathic Arthritis
Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)
This study assessed the initial efficacy and safety of canakinumab over a 4 week period in patients with systemic juvenile idiopathic arthritis (SJIA) having a flare.
- Trial name
- β-SPECIFIC 1 (NCT00886769)
- Testing
- Canakinumab
- Where
- 91 sites in United States, Argentina and 20 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Sjögren Syndrome
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome
This study was to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of CFZ533 (iscalimab) in patients with Sjögren's Syndrome (SjS).
- Trial name
- TWINSS (NCT03905525)
- Testing
- CFZ533
- Where
- 71 sites in United States, Argentina and 21 more
- Volunteers
- 273 people
- Sponsor
- Novartis Pharmaceuticals
Osteoarthritis, Avascular Necrosis
Cormet Post-PMA Study: New Enrollment
The primary objective of this study is to evaluate the performance of the Cormet Hip Resurfacing implant system in the post-approval environment.
- Conditions
- Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis
- Trial name
- PASNew (NCT00722007)
- Testing
- Cormet Hip Resurfacing
- Where
- 6 sites in United States
- Volunteers
- 147 people
- Sponsor
- Corin
Rheumatoid Arthritis
The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis
The purpose of this study is to evaluate the long-term safety and tolerability of CDP6038 (olokizumab) treatment in adult subjects with active rheumatoid arthritis (RA) who completed study RA0083 [NCT01463059].
- Trial name
- NCT01533714
- Testing
- CDP6038 (olokizumab)
- Where
- 32 sites in Japan, South Korea and 1 more
- Volunteers
- 103 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Rheumatoid Arthritis
An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies
This single-arm study evaluated the long-term efficacy and safety of tocilizumab in participants who had completed treatment in the tocilizumab core studies (NCT00106522 [Roche protocol WA18062], NCT00106574 [Roche protocol…
- Trial name
- NCT00720798
- Testing
- Tocilizumab, Disease-modifying anti-rheumatic drugs, Non-steroidal anti-inflammatory drugs
- Where
- 295 sites in United States, Argentina and 32 more
- Volunteers
- 2,067 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)
This extension study will evaluate the safety (including immunogenicity) of treatment with rituximab-Pfizer, as well as the safety and immunogenicity after transitioning from rituximab-US or rituximab-EU to rituximab-Pfizer.
- Trial name
- NCT01643928
- Testing
- Rituximab-Pfizer (PF-05280586) x 3 courses, Rituximab-EU+ Rituximab-Pfizer x 2 Courses, Rituximab-US + Rituximab-Pfizer x 2 Courses
- Where
- 71 sites in United States, Australia and 8 more
- Volunteers
- 185 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging
Determine the localization of Tc 99m tilmanocept by SPECT and SPECT/CT imaging in subjects with active RA and concordance with clinical symptomology.
- Trial name
- NCT02683421
- Testing
- Tilmanocept
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Navidea Biopharmaceuticals
Rheumatoid Arthritis
A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment
The objective of this study was to verify the efficacy of ASP015K versus placebo administrated in combination with methotrexate (MTX) over placebo in terms of efficacy in participants with rheumatoid arthritis (RA) who had an…
- Trial name
- NCT02305849
- Testing
- Peficitinib, Methotrexate
- Where
- 146 sites in Japan
- Volunteers
- 519 people
- Sponsor
- Astellas Pharma Inc
Rheumatoid Arthritis
Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
This multi-center, observational study will evaluate the clinical practice patterns, efficacy and safety of RoActemra/Actemra in patients with rheumatoid arthritis who have had an inadequate response (or were intolerant to)…
- Trial name
- NCT01579006
- Testing
- Tocilizumab
- Where
- 14 sites in Israel
- Volunteers
- 184 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice
The purpose of this study was to evaluate physical activity and its changes in participants with rheumatoid arthritis (RA) who were treated with adalimumab therapy in clinical practice.
- Trial name
- PACE (NCT01756235)
- Volunteers
- 462 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA
This is a Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between CT-P13 SC and CT-P13 IV in Patients with Active Rheumatoid Arthritis (RA).
- Trial name
- NCT03147248
- Testing
- CT-P13
- Where
- South Korea
- Volunteers
- 407 people
- Sponsor
- Celltrion
Rheumatoid Arthritis
Co-Administration Of Methotrexate And CP-690,550
This study was designed to estimate the effects of methotrexate (MTX) on the pharmacokinetics (PK) of CP-690,550 when administered to subjects with rheumatoid arthritis (RA), to estimate the effects of CP-690,550 on the PK of MTX…
- Trial name
- NCT01745055
- Testing
- CP-690,550 (tofacitinib), Methotrexate (MTX)
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Pfizer